| Literature DB >> 19815015 |
Harald Hampel1, Yong Shen, Dominic M Walsh, Paul Aisen, Les M Shaw, Henrik Zetterberg, John Q Trojanowski, Kaj Blennow.
Abstract
Recent research progress has given detailed knowledge on the molecular pathogenesis of Alzheimer's disease (AD), which has been translated into an intense, ongoing development of disease-modifying treatments. Most new drug candidates are targeted on inhibiting amyloid beta (Abeta) production and aggregation. In drug development, it is important to co-develop biomarkers for Abeta-related mechanisms to enable early diagnosis and patient stratification in clinical trials, and to serve as tools to identify and monitor the biochemical effect of the drug directly in patients. Biomarkers are also requested by regulatory authorities to serve as safety measurements. Molecular aberrations in the AD brain are reflected in the cerebrospinal fluid (CSF). Core CSF biomarkers include Abeta isoforms (Abeta40/Abeta42), soluble APP isoforms, Abeta oligomers and beta-site APP-cleaving enzyme 1 (BACE1). This article reviews recent research advances on core candidate CSF and plasma Abeta-related biomarkers, and gives a conceptual review on how to implement biomarkers in clinical trials in AD. Copyright (c) 2009 Elsevier Inc. All rights reserved.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19815015 PMCID： PMC2896007 DOI： 10.1016/j.expneurol.2009.09.024
Source DB: PubMed Journal: Exp Neurol ISSN： 0014-4886 Impact factor: 5.330